Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2023 | The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD setting

Leonido Luznik • 21 Oct 2023
COSTEM 2023
General Anti-thymocyte globulin Cyclophosphamide Mycophenolate mofetil

In this video, Leonido Luznik, MD, Johns Hopkins University School of Medicine, Baltimore, MD, shares some insights into the benefits of using post-transplant cyclophosphamide/mycophenolate mofetil/calcineurin inhibitors (PTCy/MMF/CNI) as a standard of care (SOC) for graft-versus-host disease (GvHD) prophylaxis. Dr Luznik comments on the advantages of this approach, and further discusses the need for more randomized trials in this space. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Leonido Luznik

1:18
Prevention strategies for acute and chronic GVHD in patients who have undergone transplantation
Leonido Luznik • 21 Oct 2023
1:13
Promising strategies to prevent GvHD in high-risk patients
Leonido Luznik • 21 Oct 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals